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Emerging Treatments in Alzheimer’s Disease 
INTRODUCTION 
Alzheimer’s disease is a neurodegenerative disease common in the elderly. Some of the 
symptoms associated with the disease are deterioration of cognitive functions and loss of 
memory (3). These result in lowered ability to perform daily functions. For late-stage 
patients increased symptoms of dementia (7), including confusion, personality and speech 
changes, and eventually an almost vegetative state (9). While there are currently 4 million 
people that have the disease in the United States, it is estimated that by 2050 there will be 
over 16 million people living with Alzheimer’s (9). One reason for this large increase in 
incidence and prevalence of Alzheimer’s is the increase in life span, which has occurred 
due to the improved medical care over the last century (21). AD is already the third most 
costly medical condition in the US (22), and this combined with the large number of 
people that will be reaching the elderly stage (over 65) in the next few decades, it is 
important to find an efficient treatment for this disease, since the current therapies do 
little to help.  This review will look at emerging treatments in AD. First, it will give 
background on the disease, its pathology and current treatments. Newer therapies that 
may open up new treatment pathways will then be the focus.  
BACKGROUND 
There are several factors that have shown predisposition to this disease. There are several 
genetic factors, one that includes possession of a copy of the epsilon 4 variant of the 
apolipoprotein E gene (APOE4), which increases risk by a factor of 3 (having two copies 
of the gene increases risk by a factor of 10) (2). Another set of genetic variations, one on 
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the portion of chromosome 21 that codes for the amlyoid precursor protein (APP), and 
another on chromosome 14 in the presenilin-1 and -2 genes, both can result in Familial 
Alzheimer’s Disease (FAD). These genetic mutations result in FAD, which accounts for 
30-50 % of autosomal dominant, early onset cases (most with FAD present with 
symptoms between 40 and 65) (5). However, exposure to metals, smoking, high levels of 
cholesterol, and diabetes has also been shown to be factors in increased risk (8). We 
currently do not know if these cause AD or only correlate with the disease. Age is also 
one of the leading risk factors in the development of AD. 
When a patient presents with Alzheimer’s, several steps are involved in providing 
a positive diagnosis. First, a detailed history is compiled, followed by a standardized 
assessment of cognition and functional status and laboratory testing. For brain images, 
the majority of people undergo a magnetic resonance imaging (MRI) process to exclude 
other conditions and measure brain atrophy. Other doctors will choose to use biomarkers 
to determine if a patient is presenting with AD. Specifically, doctors would be looking for 
a quantification of amyloid-β species and tau species in certain body fluids, because these 
proteins are so closely linked to the pathology of Alzheimer’s. In its prodromal stage, 
cerebrospinal fluid, obtained by lumbar puncture, appears to contain the most reliable 
biomarkers for testing for Alzheimer’s. At later stages in the disease, cerebrospinal fluid, 
plasma, and urine can all be used to identify biomarkers (22). These steps are important 
in determining whether or not a person has Alzheimer’s, yet unfortunately it can be 
expensive for someone to pay for these tests, mainly the MRI, especially if they do not 
have medical insurance (16).  
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Recently, a gene-based blood test was found to identify prodromal Alzheimer’s 
with an accuracy of 81%. These results are based on three 2-year studies on more than 
200 subjects. The blood test uses 25 genes that are known to be active in the biological 
processes associated with AD, including oxidative stress, neuronal function, and 
regulating the processing of amyloid and tau. It is believed that this test will be ready to 
be submitted to the US Food and Drug Administration within the next year. If this blood 
test is approved, it would most likely be conducted at a primary-care physicians office, 
with results back in a few days. This test should provide an effective way of diagnosing 
AD without doing an invasive procedure to look at biomarkers (26).  
There are several pathological pathways that are associated with AD. The first is 
accumulation of proteins, namely neurofibrillary tangles and β-amyloid. The 
accumulation of these tangles is caused by hyperphosphorylation of cytoskeletal tau 
protein, along with deposition of amyloid-β protein as senile plaques (3). In AD, 
glycosylation is reduced in brain tissue, which appears to alter neuronal function, most 
likely through the hyperphosphorylation of specific tau proteins. Hyperphosphorylation 
of tau seems to cause tau to aggregate, which results in the neurofibrillary tangles that are 
characteristic of Alzheimer’s (17). A second pathway that could to AD is severe neuronal 
death. This is caused by glutamatergic excitotoxicity (excessive stimulation). The 
neuronal death takes place by one of two mechanisms. One pathway causes delayed 
neuronal apoptosis when there is moderately excessive intraneuronal calcium influx, 
coupled with oxidative stress. The other pathway causes immediate neuronal death when 
there is severely excessive intraneuronal calcium influx (12). Both of these mechanisms 
of neuronal death result in the loss of memory and learning, which are key symptoms of 
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AD. A final pathological process that is associated with AD is the production of reactive 
astrocytes in the entorhinal cortex, hippocampus, amygdala, and areas of the temporal, 
parietal, occipital, and frontal cortex (13).  
Evidence has shown that one of the first places to be affected in the course of the 
disease is the hippocampus, which is important in both memory and learning. The 
hippocampus lies under the medial temporal lobe of the brain, one on each side. Based on 
this, a potential therapy has evolved, involving preserving the production of new neurons 
in the hippocampus. Several molecules that are key to AD pathogenesis are also 
important in regulating neurogenesis in the hippocampus, so it has been thought that if 
this neurogenesis can be increased, it might be an effective treatment against the disease. 
One way this therapy was tested was by looking at physical exercise and/or exposure to 
an enriched environment (EE), a positive regulator of neurogenesis. This showed an 
increase in cognitive performance in transgenic mouse models of AD. However, in 
transgenic mice with different models of AD (FAD-linked PS1 variants or forebrain-
specific PS1 knockout mice) an enriched enviroment does not enhance neurogenesis. 
Even further, EE in APOE4 transgenic mice actually suppresses neurogenesis. This 
indicates that the impact of physical exercise and EE on neurogenesis vary among 
different types of mouse models of AD. More experiments need to be done investigating 
the impact of exercise and EE on mice with different aspects of AD pathology in order to 
truly determine the effectiveness of this therapy (3). 
At this point, there are three main mechanisms that have been shown to explain 
the causes of Alzheimer’s disease. In the first, amyloid plaques, because of extracellular 
aggregation of Aβ42 peptide, create inflammation and oxidant stress. The second 
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mechanism describes neurofibrillary degeneration from an increase in phosphorylation of 
tau protein aggregating in neurofibrillary tangles. The final mechanism involves 
glutamatergic neuronal excitotoxicity due to the localization of amyloid beta peptides and 
phosphorylated tau, which leads to increased calcium entering the postsynaptic neuron. 
This ends in neuronal necrosis and apoptosis. The problem with developing a treatment 
for AD is that it might combat one of the mechanisms, but not necessarily the other two. 
Also, testing new drugs is challenging, because most require patients with no 
neurodegenerative lesions at the very earliest stages of AD. Because of the difficulty in 
recognizing Alzheimer’s at this stage, there is a very limited selection of patients (14). 
This early stage, called prodromal Alzheimer’s, was first recognized as a concept 
in 2000 to refine the concept of mild cognitive impairment. Mild cognitive impairment 
(MCI) was broken up into three categories to make treatment easier, one being ‘MCI of 
Alzheimer type’ (aka: prodromal Alzheimer’s). By associating a form of MCI with 
Alzheimer’s, it allows for the possibility of preventing full-onset AD prior to the onset of 
symptoms. Diagnostic criteria for prodromal AD include memory complaints, 
progressive onset, mildly impaired complex activities of daily living, persistence of 
memory changes after assessment, absence of the fully developed dementia, and 
exclusion of other disorders that could cause MCI (through test, neuroimaging, and 
biomarkers). One of the primary criteria for differentiating prodromal AD from other 
forms of MCI is amnestic syndrome of the hippocampal type (one of the main areas of 
the brain impacted by AD). These include the inability to free recall information, despite 
adequate cueing, and decreased total recall due to impaired recognition (27). 
CURRENT DRUGS 
 6
Since AD patients present with loss of cortical neurons and cholinergic function, the 
initial targets for treatment were cholinesterase inhibitors (ChEIs). ChEIs are one of two 
current FDA approved drugs for AD, and are used in mild to moderate cases. The most 
common ChEI prescribed is donepezil, which works to protect the cholinergic neurons 
from degeneration. Memantine, a N-methyl-D-aspartate (NMDA) receptor antagonist, is 
the other drug, and is used in moderate to severe cases. This drug was developed because 
increased activation of NMDA receptors is thought to lead to neuronal death. Both 
classes of drugs are shown to have side effects, with memantine most frequently 
reporting dizziness, headache, and constipation (25), and donepezil reporting 
nausea/vomiting, insomnia, and diarrhea. In combination with these side effects is the 
fact that both drugs only provide symptomatic relief, and do nothing to alter disease 
progression. This lack of treatment is the reason that so many new treatment methods are 
currently being worked on, with three different treatment goals being looked at: 
preventative, disease-modifying, and symptomatic (9). 
NEW TARGETS 
Competitive Inhibitors 
One focal point for new therapies is a membrane imbedded protease γ-secretase, which is 
an enzyme involved in the increased production of the amyloid-β peptides. The only γ-
secretase substrate that has been linked to Alzheimer’s is C99, which is a 99-amino acid 
long C-terminal domain of Amyloid Precursor Protein (APP). This C99 substrate has 
been shown to contain 25 amino acids of which mutation could result in FAD mutations. 
When tested, it has been shown that FAD mutations mainly affect the enzyme’s 
interaction with the C99 substrate, yet the active site remains intact. There is a sequence 
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along the C99 substrate, the Aβ sequence, which is attributed to AD when there is an 
increase in the Aβ42/Aβ40 ratio. The lowest ratio is produced when Aβ40 is the 
dominant product of the Aβ sequence, which is the normal result. When there is either a 
gain in production of Aβ42 or a loss in production of Aβ40, then the risk of AD 
increases. A 30% decrease in Aβ40 production was observed in studies of the disease 
pathogenesis, while those with no change in Aβ40 production did not present with the 
disease. These results indicate that control of the Aβ sequence could be beneficial in 
decreasing risk of Alzheimer’s. 
Multiple studies have been conducted on humans, experimental animals, and cells 
that show that in all cases of gradual saturation of γ-secretase, molecular events have 
occurred that are associated with the pathogenesis of the disease. Based on these findings, 
a therapy needs to be designed that decreases the amount of enzyme saturation with its 
C99 substrate. The ideal therapy would increase the Km (the Michaelis-Menton constant, 
a concentration value) for C99 substrate, but would be a standard competitive inhibitor of 
Aβ 1-40 and would have little to no effect on the Aβ42/Aβ40 ratio. These therapies need 
to be competitive inhibitors, because noncompetitive inhibitors, such as DAPT (N-[N-
(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester), cause a decrease in 
enzyme catalytic capacity, making the enzyme saturated even at lower than normal levels 
of C99 substrate, which is contradictory to what is desired. Further studies have shown 
that different genetic mutations have shown an increase in the Aβ42/Aβ40 ratio when the 
catalytic capacity of γ-secretase is decreased. A therapy has to combine decreased 
saturation of the C99 substrate with a competitive inhibitor that will not cause the enzyme 
to become prematurely saturated (4).  
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Selective Inhibitors 
Several drugs have been developed with an impact on the cholingeric system that are 
mainly selective inhibitors of acteylcholinesterase (AChE). Compounds inhibiting AChE 
can bind at three places; if they bind at the active site they will interact with esteratic or 
the anionic site. They could also interact with the aromatic gorge or the periperal (β) 
anionic site. Inhibitors of the esteratic subunit of the active site are usually nerve agents, 
many toxins or pesticides. One of these inhibitors is rivastigmine, a symptomatic drug 
treatment for AD and Parkinson’s. While inhibitors at the esteratic site are non-reversible, 
compounds that interact with the anionic site are reversible. Tacrine (9-amino-1,2,3,4,-
tetrahydroacridine, marketed under the name Cognex) is one such anionic site inhibitor. 
Tacrine would be promising treatment for AD, unfortunately it has high hepatotoxicity, 
so until a less toxic derivative of tacrine is found, it must be used selectively. 
Galantamine, an alkaloid from the Caucasian snowdrop (Galanthus woronowii), 
marketed under the name Nivalin, is an anionic site inhibitor, as well as an aromatic 
gorge inhibitor. While all these are promising, the main targets of AD treatment are 
inhibitors of the peripheral anionic site, because they are considered not only 
symptomatic but also possibly causative ones. Examples of drugs of this type are man-
made donepezil, trade name Aricept, and huperzine, which come from the firmoss 
Huperzia serrata. Drugs that bind at the peripheral and anionic site cause elevated levels 
of AChE, while drugs that bind at the esteratic site do not change AChE levels. 
Unfortunately, the increase in AChE is a downside to the treatment efficacy, but other 
than this AChE increase peripheral anionic site drugs are proving to be a promising 
causative treatment for AD (20).  
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Enzyme Therapy 
With the assumption of Aβ plaque buildup being a main cause of Alzheimer’s, several 
enzymes have been targeted as possible treatments. The first target is β-secretase, which 
cleaves APP, and the amount of Aβ generated is regulated by the extent of APP cleavage. 
Therefore, it has been thought that if you can inhibit the β-secretase, the Aβ plaques will 
not be formed.  
The other treatment target is γ-secretase. This enzyme contains several integral 
membrane proteins. The most common substrate of γ-secretase is APP, which produces 
Aβ40 and Aβ42 peptides. Based on this, if the production of γ-secretase were halted, then 
the production of Aβ would also decrease, reducing the plaque buildup, and possibly 
stopping neurodegeneration. In addition, the major subunit of γ-secretase is PS1/PS2, 
which has multiple mutations that cause FAD. Studies were conducted that showed that 
reducing PS1 levels increased the amount of Aβ42, but did not affect Aβ40. In contrast, 
when γ-secretase was increased by expressing all four of its subunits, the Aβ42/Aβ40 
ratio was reduced. A reduction in this ratio is an effect that is contrary to that shown with 
FAD mutation of PS1. These studies show that FAD mutations lead to loss of function, 
and that loss of function seems to affect γ-secretase processing rather than PS1 or PS2 
functioning. Based on these results, γ-secretase has been tested to see whether it would 
really treat AD if γ-secretase were inhibited. Unfortunately, a loss of γ-secretase function 
showed an increase in cancer, as well as an increase in a severe form of acne inversa; 
therefore it would not make a good treatment. Further research must be done to determine 
whether inhibition of β-secretase would cause any adverse affects (8). 
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Antioxidants 
One preventative approach being studied is antioxidant therapy. It has been shown that 
early in the disease, reactive oxygen species (ROS, produced in the mitochondria) 
damage is present (from leakage from the mitochondria), so it would make sense to treat 
with antioxidant therapy. A plus of this treatment would be that antioxidants are available 
through dietary means, making it easy and cheaper than most drugs. Several studies 
found folate supplementation to show a reduced risk of Alzheimer’s. In addition, therapy 
with both vitamins E and C has shown reduced incidence of AD, and vitamin E may 
actually slow the progression. While dietary antioxidants are used, so are pharmaceutical 
antioxidants, namely mitochondrial antioxidants. One therapy tested, Coenzyme Q10 
(CoQ10) shows neuroprotective effects, including inhibition of toxic free radical 
production and reduced ROS injury. Unfortunately, this treatment only works with fully 
intact and functioning electron transport chains (ETC), because CoQ10 is responsible for 
carrying high-energy electrons through oxidation and reduction in the ETC. Since 
damaged mitochondria, and consequently damaged ETCs, are common in early AD, this 
treatment is not practical for anyone already showing symptoms of AD. While CoQ10 
does not seem feasible as a treatment method, a similar compound, MitoQ, is shown to 
have the same effects as CoQ10 (reduced ROS injury), it does not require a fully intact 
ETC to work properly, since it is not as involved in the chain as CoQ10 is (9).  
Hormones 
Hormone levels are promising in as a disease modification therapy. Altered hormone 
levels appears to play a role in AD, which is shown in the increased incidence of AD in 
women, since they experience hormone changes when going through menopause. The 
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most drastic hormone change during this time is luteinizing hormone (LH), which 
doubles in production. The significance of this hormone change is further exasperated by 
the fact that men with Down’s syndrome, who have elevated LH levels, are more likely 
to develop AD than women with Down’s. This trend, similar to women who have 
experienced menopause, shows a direct link between AD and LH level. Overall, patients 
with AD show LH concentrations twice as high as non-AD patients the same age. A new 
drug, leuprolide acetate, has been shown to reduce these LH levels, and in Phase II 
clinical trials decreased cognitive decline and stabilized activities of daily living in 
patients with mild to moderate Alzheimer’s. Based on these findings, therapies to 
decrease LH look to be a very promising treatment (9).  
The major secretion from the adrenal gland, dehydroepiandrosterone (DHEA), 
has been shown to slow delay brain aging by recovering the impairment of growth 
factors. A decrease in DHEA production is the most common age-related change in the 
adrenal cortex. DHEA also has antioxidant, anti-inflammatory, and ultimately anti-aging 
affects. While DHEA has been proven to be effective therapy in non-elderly patients with 
cognitive decline, it has yet to be tested in patients with advanced age. Therefore, a study 
was conducted testing the ability of DHEA as a treatment in experimental AD rodents by 
measuring oxidative stress biomarkers, antioxidant status, neurotropic factor BDNF, and 
cholinergic markers. The data from the study concluded that DHEA produced significant 
increase in oxidative stress markers, activation of the antioxidant enzymes, and 
enhancement of BDNF and acetylcholine levels. Based on these results, it can be 
concluded that DHEA has an important role in characterizing AD through its antioxidant, 
neurotrophic properties, and cholinesterase-inhibiting activity. Since this experiment was 
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completed on rats, the next step is putting together a clinical trial in order to see if these 
same properties apply in a human model (13).  
Sex Hormones 
Sex hormones have also shown to have protective actions against Alzheimer’s. While sex 
hormones are currently recognized for their neuroprotective properties, translating these 
into an efficient treatment or prevention strategy for AD has been largely unrecognized, 
even though evidence suggests that neural actions estrogens, androgens, and possibly 
progestogens can reduce the risk of AD (23).  
The most important of these sex hormones might be estrogen, which was brought 
to the attention of researchers due to the higher prevalence and incidence of AD in 
females. There is a stronger association between the apolipoprotein E allele in women 
than men, as well as a greater severity of AD in women indicated by differences in 
neuropathy and cognitive deficits between sexes. These both indicate that women might 
be at a higher risk for AD, even when their longer lifespan is taken into account. Several 
studies were done in transgenic mouse models that exhibit sex differences in AD-like 
neuropathy similar to humans, mostly through a greater Aβ deposition that was observed 
in female mice, which suggest the female brain might be more vulnerable (23). 
This increased risk is presumed to be associated with the loss of estrogens and 
progesterone that women suffer at menopause. Further, compared to women of the same 
age without AD, women with AD have even lower levels of estrogen. Estrogen has the 
ability to protect against neuronal loss induced by the neurodegenerative agent Aβ, and 
several reports show estrogen to protect neurons and neural cell lines from Aβ mediated 
toxicity and could promote Aβ. Estrogen might also regulate APP processing through 
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protein kinase C (PKC) dependent pathways. Also, estrogen and progesterone both have 
the ability to regulate levels of tau phosphorylation (23).  
Estrogen has been studied alone, as well as estrogen combined with progesterone. 
However, multiple reports show that progesterone often antagonizes the estrogen-
mediated neuroprotective actions, rather than synergizing with the estrogen. One drug, 
tamoxifen, an antiestrogen most commonly used to treat breast cancer. It has been found 
that low concentrations of tamoxifen can protect cultured neurons from toxicity due to 
Aβ. This suggests the possibility of tamoxifen’s use as a potential treatment against AD. 
Because this is a new finding, the potential benefits of tamoxifen in postmenopausal 
women for prevention and/or treatment of Alzheimer’s has not been well studied, but 
should be seriously considered for research based on the information presented (23). 
Antidepressants 
A symptomatic approach being tested involves antidepressants. About 35% of 
Alzheimer’s patients develop depression at some point during the disease. Patients with 
AD have an insufficient amount of the neurotransmitters dopamine, norepinephrine, and 
serotonin, because of cortical atrophy. Selective serotonin reuptake inhibitors (SSRIs) 
have been shown to improve depression and enhance quality of life. In addition, 
antidepressant therapy is the only therapeutic intervention that has shown significant 
improvement in patients with mild impairment. All of these treatments have shown to 
improve the quality of life for AD patients, and some have shown to slow disease 
progression, but in the future it is important to keep testing them in trials, and to combine 
them with other therapies to get the maximum therapeutic benefit for the patient (9).  
Combined Therapies 
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Donepezil is now being paired with other drugs in order to maximize treatment, since it is 
one of the few drugs that have shown any positive improvements. Studies have been done 
that indicate that improving blood supply to the brain might help in the treatment and/or 
rehabilitation in AD patients, so donepezil has been paired with natural hirudin, a direct 
thrombin inhibitor, which varies from normal anti-coagulants in that does not have the 
potential to cause bleeding or inhibit blood-clotting. To test this, a study was done using 
84 patients testing treatment with donepezil alone and donepezil combined with hirudin. 
At the beginning of the trial, each patient received an Alzheimer’s Disease Assessment 
Scale cognitive (ADAS-Cog) score ranging from 0-70, with the higher score indicating 
more cognitive impairment. In the patients treated with the combined treatment had a 
significant decrease in ADAS-Cog scores. When you compare this result to the donepezil 
group alone, the scores in the combined treatment group were lowered by a significantly 
larger amount than in donepezil alone. Cognition was also improved in the combined 
group over an 8-week period. While there was a statistical significance between the two 
groups, a larger study would be conducted in order to get a further understanding of the 
effectiveness of the combined therapy, as well as a study that takes place over a longer 
period of time, to determine the lasting effects of the results (the current study lasted only 
20 weeks) (7).  
Memantine, the NMDA discussed earlier that is approved by the FDA, has no 
immediate treatment effect. However, after 3 to 6 months of use, patients have reported 
better cognitive performance. This makes sense, because memantine is used to treat 
symptoms and help to slow disease progression, but does not stop it completely. When 
treating with memantine, neuronal death still occurs, so it was hypothesized that coupling 
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memantine with an antioxidant would be better at protecting against neuronal death and 
declines in cognitive performance. The antioxidant chosen to test this was vitamin D, 
which is hormone that crosses the blood-brain barrier and binds to receptors in the central 
nervous system. Not only has vitamin D been known to help cognitive decline, but it also 
has been shown to improve gait performance, another complication of AD. The pathways 
of hypovitaminosis D and cognitive decline in Alzheimer’s are smiliar, with both based 
on the calcium neurotoxicity and the changes in protective mechanisms against 
glutamatergic excitotoxicity. It is for this reason that vitamin D was chosen as a couple to 
memantine for a study in combination treatment. For the results, a decrease on the 
ADAS-Cog score of at least 3 points will be considered relevant. This trial is currently 
being recruited for completion, yet based on the initial findings and the positive aspects 
of each on their own, the findings from the trial are expected to be positive for coupling 
memantine with vitamin D in treating cognitive decline in Alzheimer’s patients (12). 
A study was conducted that involved determining the effects of continued 
donepezil treatment on patients living in community-living residencies, and whether or 
not adding memantine to this treatment was beneficial. The study had three objectives. 
The first, to test whether over a 1-year period continued or discontinued donepezil 
treatment was more effective in improving cognition. The second objective was whether 
or not the addition of memantine was helpful, and the third, to test if the combined 
treatment would have additive or syngeristic benefits. After the one-year test period, the 
following results were found. Continuing donepezil showed significant improvement on 
the Standardized Mini-Mental State Examination (SMMSE), and while memantine 
therapy allowed showed an improvement in SMMSE scores, it was not as large as the 
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donepezil therapy. In regards to the third objective, it was found that combined treatment 
with both donepezil and memantine was not significantly better than treatment with 
donepezil alone. These results show that the first two objectives had statistically 
significant positive results, while the third objective did not (15).  
Immunotherapy 
Amyloid-β (Aβ) immunotherapy is an emerging approach to combat AD, yet it appears 
to be most effective in treating the disease in its later stages. In searching for a therapy to 
combat early disease pathology, it was hypothesized that anti-inflammatory cytokine 
signaling, specifically interleukin-4 (IL-4), efficiently enhances Aβ clearance, synaptic 
transmission, and amelioration of AD progression. This was tested on mice, and the 
results showed that IL-4 enhances neurogenesis in mouse neural progenitor cells 
cocultured with IL-4 stimulated microglia in the presence of Aβ peptide. This study was 
the first that showed that central nervous system expression of IL-4 could directly 
stimulate neurogenesis. This suggests that IL-4 is likely to enhance neuronal progenitor 
cell proliferation, and neuronal differentiation. It was shown that neuronal expression of 
the anti-inflammatory interleukin-4 restores the spatial learning function of mice through 
its effect on Aβ reduction, glial activation, and neurogenesis. The study also showed that 
IL-4 could function as neuromodulators or neurohormones. These results all show that it 
should be possible to treat neurodegenerative disorders through anti-inflammatory 
signaling cascades in the brain (19).  
Antiviral Agents 
There is increasing evidence that herpes simplex virus 1 (HSV1), a neurotropic virus 
infecting most humans and causes herpes simplex encephalitis (HSE), has a role in 
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Alzheimer’s. This connection was first established because in those affected with HSE, 
the same areas of the brain are impacted as those in AD. Since the virus is also present in 
many older adults, and those with the apolipoprotein E gene, which has been linked to 
AD, it was suggested that HSV1 is connected to Alzheimer’s. Because of this, it has been 
hypothesized that an antiviral agent would be beneficial in treating AD. Most antiviral 
agents currently target viral DNA replication. Therefore, it had to be determined if the 
accumulation of Aβ and tau protein, important steps in the formation of the disease, 
occurred through the process of viral DNA replication or independently of the replication 
process. A study was done to determine which pathway this accumulation followed. It 
was determined that tau protein formation is dependent on viral DNA replication directly 
(or on a protein dependent on it). Three antiviral agents were tested, acyclovir, 
penciclovir, and foscarnet, and all three inhibited tau formation. Conversely, when Aβ 
accumulation was tested, it was not completely inhibited by the antivirals, although it was 
partially inhibited (accumulation of about 20-30% of the normal amount was left, when 
the antivirals were used in high doses). The results of this study show that an antiviral 
agent would not only stop HSV1 replication, it would also provide effective treatment for 
Alzheimer’s disease (11).  
Allopregnanolone 
It has been previously demonstrated that allopregnanolone (APα) increased proliferation 
of neural progenitor cells in vitro. The optimal treatment regimen of APα was found to 
be APα administered once a week for 6 months for promotion of neurogenesis and 
reduction of AD effects. During the study that determined this optimal treatment, it was 
indicated that APα is most effective in the pre-pathology, or very early stages, of the 
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disease. The appearance of the amyloid-β plaques coincides with the end of APα 
efficacy. The deposition of Aβ in the extracellular components of the cell leads to this 
loss of efficiency. This data indicates that the key point in regulating therapeutic efficacy 
is the presence of intraneuronal Aβ plaques. Overall, APα would be most beneficial 
when brains still have neurogenic and myelination capacity, meaning this treatment could 
only be used in patients with very early stage AD, or in those diagnosed with general 
mild cognitive impairment (10).  
Sleep Therapy 
Many patients suffering from AD are subject to sleep disturbances, which can lead to 
increased risk for physiological and physical problems. Sleep problems are one of the 
leading factors in patient institutionalization, because it affects both patient and caregiver. 
Sleep disturbances can be hard to treat, because sedatives can have many side effects. 
Because of this, two alternate therapies were suggested, increased daytime activity and 
bright light therapy, or a combination of the two. During a two month active treatment 
period, patients were awake for an average of 37 minutes per night less than the control 
subjects, and were overall asleep a greater portion of their time spent in bed, for all 
treatment methods (daytime activity, light therapy, or a combination). Unfortunately, 
sleep improvements were not sustained at the six-month posttest point. Based on these 
results, it can be deduced that if this treatment were continued with caregiver assistance, 
it would improve sleep the longer that the therapy was in use (1).  
Treatment Facility 
Many people wonder whether they should be treated at memory clinics for their AD, or 
whether their general practitioner would be sufficient in treating the disease, so a study 
 19
was conducted to determine the effectiveness of the two types of post-diagnosis 
treatment. Participants were assigned to one or the other, and then treated for a period of 
a year. Results were based on patients scores based on different scales. After the study, 
no evidence was found showing a difference in effectiveness between the memory clinics 
and general practitioners based on treatment and coordination of care. The only 
difference shown between the two was that the general practitioner group had a small 
positive effect on anxiety and the mood of the caregivers, although this result was not 
statistically significant (6). 
Reduction of Aβ: 
 End-stage Alzheimer’s has been shown to trace back to one simple process, the 
ordered aggregation of amyloid- β in the brain. While researchers cannot agree on how 
Aβ aggregation actually distrupts the brains function, it has been shown that reducing the 
amount of Aβ present will be sufficient to provide a therapeutic treatment. There are 
three ways this therapy could be achieved. First would be to inhibit the enzymes that 
cause Aβ to release from its parent protein. A second therapy would be to promote 
cellular Aβ degradation, and third, to stimulate immune-mediated removal of Aβ. All of 
these treatment options should provide a therapy for AD, although a combination might 
be required in order to provide full efficacy (24). 
SUMMARY 
Several new therapies have been studied in regards to the treatment of Alzheimer’s 
disease, many with promising outlooks. This review has given a background of the 
disease along with the current available treatments, and then indicated emerging 
treatments that are being focused on. Several of these emerging treatments have been 
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shown to improve the quality of life in patients, and a few have also proven to slow 
disease progression. Therefore, future research should focus on the treatments described 
above and the testing of them in clinical trials, especially in the area of combined therapy, 
which researchers believe will provide the maximum benefit to the patient. There has 
been strong evidence that the disease pathology starts much earlier than symptoms show 
(18). So, while it is hard to find patients that fit the criteria of AD, trials should focus on 
patients at the earliest stages of the disease, because if an effective treatment can be found 
at that stage, treatments for moderate to late stage AD will not be necessary (not to 
mention patients and their families will not have to suffer through late stage AD). All of 
the treatments discussed above are promising, and hopefully through further research 
one, or more likely a combination, will provide the key to stopping Alzheimer’s disease 
progression.  
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